Informative Articles Update EP 2.6.7 – What will change for you
The revised European Pharmacopoeia 2.6.7 will come into effect in April 2026 and introduces important updates for regulatory mycoplasma testing. Many laboratories are currently evaluating how these changes will impact validation activities, routine testing and product release. Our latest article provides a clear and concise summary of the new requirements and highlights the aspects that will be most relevant for your future workflows.
If cells are part of your daily routine, this is a great chance to exchange ideas, talk openly about contamination challenges and pick up practical tips for a smoother, more reliable workflow. We’re excited to connect, hear your experiences and share insights that make everyday lab life a bit easier. Looking forward to seeing you there.
Product Highlights Robust, reproducible, and efficient nucleic acid extraction for mycoplasma detection
Reliable extraction is one of the most critical steps for accurate mycoplasma testing. Venor® Mycoplasma Extraction is a magnetic bead based system that ensures consistent DNA and RNA recovery even from challenging product matrices. The workflow requires a hands-on time of ≤15 minutes and can be performed manually or on automated extraction platforms. This enables laboratories to achieve reliable and reproducible results with minimal effort while supporting downstream applications in conventional PCR, real-time PCR and digital PCR. The kit provides a robust solution for biopharmaceutical development, ATMP manufacturing and GMP quality control.
Key Benefits
Pharmacopeia- and guideline-compliant
Validated together with new Venor® Mycoplasma product line
Suitable for typical biopharmaceutical and ATMP matrices
Use dedicated spaces for sample prep, PCR setup, and amplification. This small habit greatly reduces contamination risk and helps you maintain clean, reliable results.
